Front Matter - The Journal of Bone & Joint Surgery

More documents

Recommendations

Info

Dislocation concerns? Lifestyle Recovery Technologies Helping you to help patients maximize ROM and enhance stability. LFIT Anatomic CoCr Femoral Head with X3 Liner UHRBipolar Femoral Head Secur-Fit Max Femoral Hip Stem Trident Constrained Insert Formore information,contactyourlocal Stryker sales representative at 1-866-447-3627 or visit www.stryker.com Lifestyle Recovery Technologies, LFIT AnatomicCoCr Femoral Head, X3 Liner,UHRBipolar Head,Trident Constrained Insert Stryker Orthopaedics 325 Corporate Drive, Mahwah, NJ 07430 Asurgeon is the best person to decide with the patient which treatments andproducts are right for them. Surgeons must always rely on their ownclinicaljudgement when deciding which treatments andprocedureto use with patients. Copyright © 2006 Stryker. Stryker Corporation orits divisions or other corporate affiliated entities own, use or have appliedfor the following trademarks:LFIT, Lifestyle Recovery, Secur-Fit, Stryker, Trident, UHR, X3. Downloaded From: http://jbjs.org/ on 01/27/2014
IMPORTANT SAFETY INFORMATION: *Because of its clotting mechanism, Thrombin-JMI ® must not be injected or otherwise allowed to enter large blood vessels. Extensive intravascular clotting or even death may result. Thrombin-JMI ® should be given to a pregnant woman only if clearly indicated. Safety and efficacy in children have not been established. The use of topical bovine thrombin preparations has occasionally been associated with abnormalities in hemostasis ranging from asymptomatic alterations in laboratory determinations, such as prothrombin time (PT) and partial thromboplastin time (PTT), to severe bleeding or thrombosis which rarely have been fatal. These hemostatic effects appear to be related to the formation of antibodies against bovine thrombin and/or factor V which in some cases may cross react with human factor V, potentially resulting in factor V deficiency. Repeated clinical applications of topical bovine thrombin increase the likelihood that antibodies against thrombin and/or factor V may be formed. Consultation with an expert in coagulation disorders is recommended if a patient exhibits abnormal coagulation laboratory values, abnormal bleeding or abnormal thrombosis following the use of topical thrombin. Any interventions should consider the immunologic basis of this condition. Patients with antibodies to bovine thrombin preparations should not be re-exposed to these products. Please see brief summary of full Prescribing Information for Thrombin-JMI ® on adjacent page. Downloaded From: http://jbjs.org/ on 01/27/2014
Page 1 and 2: In a pivotal head-to-head study,* E
Page 3 and 4: Downloaded From: http://jbjs.org/ o
Page 5 and 6: EXOGEN ultrasound treatment has the
Page 9 and 10: NEW Designed by John L. Stanton, MD
Page 11 and 12: The marriage of the Uni and the PFJ
Page 15 and 16: INSTRUCTIONS TO AUTHORS THE JOURNAL
Page 17 and 18: INSTRUCTIONS TO AUTHORS THE JOURNAL
Page 19 and 20: AOA ~ KELLOGG LEADERSHIP SERIES ~ E
Page 21 and 22: PUBLISHED IN TWO VOLUMES AMERICAN V
Page 23 and 24: EDITORIAL STAFF AMERICAN OFFICE 20
Page 25 and 26: For MIS and Navigation Assisted Hip
Page 31 and 32: Experience Reserve your AAOS Annual
Page 33 and 34: Adv 32 JBJS [Br] Abstracts Now Avai
Page 35 and 36: 2006 Corporate Associates Platinum
Page 37: “ DYONICS ELECTROBLADE Resector m
Page 41 and 42: THROMBIN, TOPICAL U.S.P. (BOVINE OR
Page 43 and 44: The Main Event The comprehensive me
Page 47 and 48: ® ® ® ® ® ®
Page 51 and 52: Features of BONE FOAM • Radioluce
Page 55 and 56: T-Pin for Distal Radius Fracture Fi
Page 57 and 58: UNIQUE NATIONAL HCPCS CODE Q4084 BR
Page 63 and 64: FRAGMIN (dalteparin sodium injectio
Page 67 and 68: moving beyond simple wear reduction
Page 71: See brief summary on page 110 Downl

Front Matter - The Journal of Bone & Joint Surgery

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?